Capricor Therapeutics (NASDAQ:CAPR) Earns Overweight Rating from Cantor Fitzgerald

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report issued on Thursday,Benzinga reports. They presently have a $30.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 133.28% from the stock’s previous close.

Separately, HC Wainwright restated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research note on Monday, March 17th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Capricor Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $12.86 on Thursday. The stock’s fifty day moving average price is $14.06 and its 200 day moving average price is $14.55. Capricor Therapeutics has a 1 year low of $3.52 and a 1 year high of $23.40. The company has a market cap of $584.74 million, a price-to-earnings ratio of -12.13 and a beta of 4.10.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.15. The firm had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. Research analysts expect that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. boosted its position in Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 2,947 shares during the period. Virtus ETF Advisers LLC purchased a new stake in Capricor Therapeutics during the fourth quarter worth $68,000. AlphaQuest LLC acquired a new stake in Capricor Therapeutics during the fourth quarter valued at $78,000. Finally, New York State Common Retirement Fund boosted its stake in shares of Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 5,000 shares in the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.